Strike three: Bristol-Myers’ third I/O shot at glioblastoma misses as Opdivo flops yet again on key endpoint
Glioblastoma continues to defy about everything thrown at it.
Bristol-Myers Squibb put out word Thursday morning that its third Phase III assault on brain …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
